Champions Oncology (CSBR) Q2 2025 earnings summary

Executive summary

• Achieved strong financial rebound in Q2 and first half fiscal 2025, with net income of $2.1 million for the first half and $730,000 for Q2, reversing prior year losses.

• Revenue grew 17% year-over-year in Q2 to $13.5 million and 14% for the first half to $27.6 million, driven by core/oncology services and operational improvements.

• Cost controls and operational efficiencies led to margin expansion and reduced R&D and G&A expenses.

• New data platform and licensing revenue stream established, with a $5.0 million agreement signed in December 2024.

• Management remains focused on scalability, efficiency, and capital-raising for the drug development subsidiary, but notes going concern risks without additional financing.

Financial highlights

• Q2 revenue was $13.5 million, up 17% year-over-year; first half revenue totaled $27.6 million, up 14%.

• Q2 net income was $728,000–$730,000; first half net income was $2.0–$2.1 million, reversing prior year losses.

• Adjusted EBITDA for Q2 was $1.1 million; for the first half, $3.2 million.

• Gross margin improved to 45% in Q2 and 47–48% for the first half.

• Ended the quarter with $2.8 million in cash and no debt.

Outlook and guidance

• Projected full-year revenue growth of 10–15%, with positive quarterly Adjusted EBITDA anticipated.

• New data licensing agreement in December 2024 expected to generate $5.0 million, with an option for an additional $3.0 million.

• Management expresses confidence in strategies but cannot assure continued operations without new financing.